Bausch Health (BHC)

Executive Summary

Bausch Health is a diversified specialty pharmaceutical company with a focus on gastroenterology, dermatology, and aesthetics. Having transitioned from its Valeant past, the company now prioritizes core brands such as Xifaxan (rifaximin) for IBS-D and hepatic encephalopathy, Trulance (plecanatide) for chronic idiopathic constipation, and Siliq (brodalumab) for psoriasis. Near-term growth is heavily dependent on the FDA's decision on an sNDA for Xifaxan in IBS-D, with a PDUFA date in mid-2026. The pipeline includes an early-stage acne combination therapy (clindamycin/adapalene/BPO gel) that recently entered Phase 1 and is expected to yield data in late 2026. While debt reduction and litigation resolution remain key financial milestones, the company's commercial portfolio provides stable cash flow. However, heavy reliance on Xifaxan and high leverage constrain conviction. Overall, Bausch Health represents a turnaround story with significant near-term binary risk from the Xifaxan label expansion decision.

Upcoming Catalysts (preview)

• Q2 2026FDA decision on Xifaxan sNDA for IBS-D70% success
• Q4 2026Phase 1 data readout for acne combination gel (clindamycin/adapalene/BPO)60% success
• Q3 2026Debt reduction update or refinancing announcement80% success